PSI Journal Club: Limitations and Challenges with Mixed Model Repeated Measures (MMRM) Analysis
Moses Mwangi and Florian Lasch present their recent work on MMRM, with discussion lead by Geert Molenberghs.
This 1-day scientific meeting will provide an update on latest trends in HTA, including: the Real-World Evidence Navigator tool created by the IMI GetReal project; the EUnetHTA Joint Action 3 initiative and methodology being researched; introduction to value-based frameworks and estimands in HTA. Patient perspectives in HTA will be discussed including how to involve patients in HTA and latest methods in patient reported outcomes. HTA related methodological considerations will be highlighted including approaches to handle treatment switching in HTA. Industry HTA case studies will also be presented.
Speakers include well known representatives from academia, European regulatory bodies and industry. The day will end with a panel discussion.
To download the flyer please click here.
09:30 | Welcome Chrissie Fletcher (Amgen, Chair HTA SIG), William Malbecq (MSD) |
09:50 | Session: Trends in HTA(1) Introducing the RWE Navigator - Heather Stegenga (NICE) EUnetHTA Joint Action 3 activities - Zoe Garrett (NICE) |
11:10 | Coffee Break |
11:30 | Session: HTA research and methods Adjusting for treatment switching in randomised controlled trials - Nick Latimer (University of Sheffield) Accumulated Industry experience in bridging regulatory and HTA research methodologies - William Malbecq, Kristel Vandormael (MSD) |
12:50 | Lunch |
13:30 | Session: Patient perspectives in HTA Involving the patient in HTA - Karen Facey (Evidence Based Health Policy Consultant) Benefit-risk Assessment in HTA - Shahrul Mt-Isa (MSD), Susan Talbot (Amgen) |
14:50 | Coffee Break |
15:10 | Session: Trends in HTA(2) Value-based frameworks - Jan McKendrick (PRMA Consulting) Estimands in HTA- Jason Wang (Celgene), Chrissie Fletcher (Amgen) |
16:30 | Panel Discussion |
17:00 | Summary and meeting close |
Registration on or before 14th October | |
PSI Member | £100 (plus VAT) |
Non-Member | £140 (plus VAT) |
Academic | £70 (plus VAT) |
Registration after 14th October | |
PSI Member | £120 (plus VAT) |
Non-Member | £160 (plus VAT) |
Academic | £90 (plus VAT) |
Moses Mwangi and Florian Lasch present their recent work on MMRM, with discussion lead by Geert Molenberghs.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Talks from speakers will cover an introduction to HTA and indirect comparisons for value assessment before focusing in more specifically on topics related to the use of indirect treatment comparisons for patient access.
Talks from the speakers will cover the use of R in a programming community, submitted to regulators using R, and also programming beyond R in C++ and Julia.
This course is aimed at clinical trial statisticians who are new to or with limited experience of machine learning. Attendees will learn about a range of topics in machine learning, including practical sessions in R.
This webinar will explore two different approaches to Correlates of Protection in vaccine development.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.